Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1Breast 1

Conditions

Neoplasms 2Colorectal Neoplasms 2Malignant Solid Tumor 1Breast Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × etirinotecan pegol × Clear all
NCT00598975 2021-07-12

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Nektar Therapeutics

Phase 2 Completed
18 enrolled 13 charts
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT00856375 2021-07-12

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Nektar Therapeutics

Phase 2 Completed
83 enrolled 13 charts
Gastrointestinal

Colorectal Neoplasms

NCT01457118 2021-07-12

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Nektar Therapeutics

Phase 2 Completed
27 enrolled 18 charts
Other solid neoplasm

Malignant Solid Tumor

NCT00802945 2018-07-09

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Nektar Therapeutics

Phase 2 Completed
70 enrolled 15 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡